Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease

Brain

Volumn 137, Issue 5, 2014, Pages 1533-1549

  Shinohara, Mitsuru ^a   Fujioka, Shinsuke ^a,b   Murray, Melissa E ^a   Wojtas, Aleksandra ^a   Baker, Matthew ^a   Rovelet Lecrux, Anne ^c   Rademakers, Rosa ^a   Das, Pritam ^a   Parisi, Joseph E ^d   Graff Radford, Neill R ^b   Petersen, Ronald C ^d   Dickson, Dennis W ^a   Bu, Guojun ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ROUEN   (France)

^d MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; amyloid ; APP; neuroanatomy; synapses

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; GLIAL FIBRILLARY ACIDIC PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95; PRESENILIN 1; TAU PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN REGION; CARBOXY TERMINAL SEQUENCE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL ALZHEIMER DISEASE; FAMILIAL DISEASE; FEMALE; GENE MUTATION; HUMAN; LIMBIC SYSTEM; MALE; NEUROPATHOLOGY; PATHOLOGICAL AGING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROCESSING; SPORADIC ALZHEIMER DISEASE; STRIATE CORTEX; SYNAPTIC TRANSMISSION;

ALZHEIMER'S DISEASE; AMYLOID-Β; APP; NEUROANATOMY; SYNAPSES;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROFIBRILLARY TANGLES; POSTMORTEM CHANGES; PRESENILIN-1; SYNAPSES; TAU PROTEINS;

EID: 84899835214     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu046     Document Type: Article

References (62)

1. Akiyama H, McGeer PL. Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med 2004; 10: 117-8.
2. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 2011; 14: 750-6.
3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
4. Bu G. Apolipoprotein E and its receptors in Alzheimers disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10: 333-44.
5. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimers disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-17.
6. Cabrejo L, Guyant-Marechal L, Laquerriere A, Vercelletto M, De la Fourniere F, Thomas-Anterion C, et al. Phenotype associated with APP duplication in five families. Brain 2006; 129 (Pt 11): 2966-76.
7. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, et al. Massive gliosis induced by interleukin-6 suppresses Ab deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 2010; 24: 548-59.
8. Chase TN. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat Disord 2004; 10: 305-13.
9. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005; 48: 913-22.
10. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimers disease increases beta-protein production. Nature 1992; 360: 672-4.
11. Dickson DW, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992; 13: 179-89.
12. Dickson TC, Saunders HL, Vickers JC. Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimers disease. Neuropathol Appl Neurobiol 1997; 23: 483-91.
13. Duering M, Grimm MO, Grimm HS, Schroder J, Hartmann T. Mean age of onset in familial Alzheimers disease is determined by amyloid beta 42. Neurobiol Aging 2005; 26: 785-8.
14. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383: 710-3.
15. Espinoza M, de Silva R, Dickson DW, Davies P. Differential incorporation of tau isoforms in Alzheimers disease. J Alzheimers Dis 2008; 14: 1-16.
16. Gearing M, Mori H, Mirra SS. Abeta-peptide length and apolipoprotein E genotype in Alzheimers disease. Ann Neurol 1996; 39: 395-9.
17. Hayashi S, Wakabayashi K, Iwanaga K, Kakita A, Seki K, Tanaka M, et al. Picks disease: selective occurrence of apolipoprotein E-immunoreactive pick bodies in the limbic system. Acta Neuropathol 1998; 95: 1-4.
18. Hesse C, Bogdanovic N, Davidsson P, Blennow K. A quantitative and immunohistochemical study on apolipoprotein E in brain tissue in Alzheimers disease. Dement Geriatr Cogn Disord 1999; 10: 452-9.
19. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimers disease model. Ann Neurol 2000; 47: 739-47.
20. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994; 13: 45-53.
21. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimers disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-16.
22. Janocko NJ, Brodersen KA, Soto-Ortolaza AI, Ross OA, Liesinger AM, Duara R, et al. Neuropathologically defined subtypes of Alzheimers disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol 2012; 124: 681-92.
23. Karran E, Mercken M, Strooper BD. The amyloid cascade hypothesis for Alzheimers disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698-712.
24. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007; 27: 6174-84.
25. Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodriguez Martinez de Llano S, Edison P, et al. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011; 134 (Pt 1): 293-300.
26. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009; 106: 4012-7.
27. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004; 10: 719-26.
28. Koivunen J, Verkkoniemi A, Aalto S, Paetau A, Ahonen J-P, Viitanen M, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimers disease. Brain 2008; 131: 1845-53.
29. Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 2006; 27: 686-95.
30. Lalonde R, Strazielle C. Brain regions and genes affecting myoclonus in animals. Neurosci Res 2012; 74: 69-79.
31. Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimers disease associated with mutations of the presenilin-1 gene. J Neurol 2006; 253: 139-58.
32. Larner AJ, Doran M. Genotype-phenotype relationships of presenilin-1 mutations in Alzheimers disease: an update. J Alzheimers Dis 2009; 17: 259-65.
33. Lee GJ, Lu PH, Medina LD, Rodriguez-Agudelo Y, Melchor S, Coppola G, et al. Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimers disease mutations. J Neurol Neurosurg Psychiatry 2013; 84: 154-62.
34. Mann DM, Iwatsubo T, Pickering-Brown SM, Owen F, Saido TC, Perry RH. Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimers disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci Lett 1997; 221: 81-4.
35. Nakamura S, Ono F, Hamano M, Odagiri K, Kubo M, Komatsuzaki K, et al. Immunohistochemical detection of apolipoprotein E within prion-associated lesions in squirrel monkey brains. Acta Neuropathol 2000; 100: 365-70.
36. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimers disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991; 541: 163-6.
37. Nishiyama E, Iwamoto N, Ohwada J, Arai H. Distribution of apolipoprotein E in senile plaques in brains with Alzheimers disease: investigation with the confocal laser scan microscope. Brain Res 1997; 750: 20-4.
38. Pellizzaro Venti M, Paciaroni M, Caso V. Caudate infarcts and hemorrhages. Front Neurol Neurosci 2012; 30: 137-40.
39. Remes AM, Laru L, Tuominen H, Aalto S, Kemppainen N, Mononen H, et al. Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 2008; 65: 540-4.
40. Ren Y, Sahara N. Characteristics of tau oligomers. Front Neurol 2013; 4: 102.
41. Ringman JM, Gylys KH, Medina LD, Fox M, Kepe V, Flores DL, et al. Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimers disease due to a novel PSEN1 mutation. Neurosci Lett 2011; 487: 287-92.
42. Rossor MN, Newman S, Frackowiak RS, Lantos P, Kennedy AM. Alzheimers disease families with amyloid precursor protein mutations. Ann N Y Acad Sci 1993; 695: 198-202.
43. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38: 24-6.
44. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-25.
45. Ryan NS, Keihaninejad S, Shakespeare TJ, Lehmann M, Crutch SJ, Malone IB, et al. Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimers disease. Brain 2013; 136 (Pt 5): 1399-414.
46. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimers disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimers disease. Nat Med 1996; 2: 864-70.
47. Shigematsu K, McGeer PL, McGeer EG. Localization of amyloid precursor protein in selective postsynaptic densities of rat cortical neurons. Brain Res 1992; 592: 353-7.
48. Shinohara M, Bu G. What can we learn from regional vulnerability to amyloid-b accumulation in nondemented individuals? Neurodegener Dis Manag 2013; 3: 187-9.
49. Shinohara M, Petersen RC, Dickson DW, Bu G. Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathol 2013; 125: 535-47.
50. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimers disease: a dual pathway hypothesis. Neuron 2008; 60: 534-42.
51. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12: 609-22.
52. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 8098-102.
53. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 2002; 161: 1869-79.
54. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-800.
55. Thies W, Bleiler L. Alzheimers disease facts and figures. Alzheimers Dement 2013; 9: 208-45.
56. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008; 283: 29615-9.
57. Vercueil L, Hirsch E. Seizures and the basal ganglia: a review of the clinical data. Epileptic Disord 2002; 4: S47-54.
58. Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 2009; 66: 1537-44.
59. Vlassenko AG, Vaishnavi SN, Couture L, Sacco D, Shannon BJ, Mach RH, et al. Spatial correlation between brain aerobic glycolysis and amyloidbeta (Abeta) deposition. Proc Natl Acad Sci USA 2010; 107: 17763-7.
60. Wojtas A, Heggeli KA, Finch N, Baker M, DeJesus-Hernandez M, Younkin SG, et al. C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. Am J Neurodegener Dis 2012; 1: 107-18.
61. Wu J, Petralia RS, Kurushima H, Patel H, Jung MY, Volk L, et al. Arc/ Arg3.1 regulates an endosomal pathway essential for activitydependent beta-amyloid generation. Cell 2011; 147: 615-28.
62. Yamaguchi H, Ishiguro K, Sugihara S, Nakazato Y, Kawarabayashi T, Sun X, et al. Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer beta-amyloid deposition. Acta Neuropathol 1994; 88: 413-9.